Belgium's Ablynx has raised about $40 million from a private placement of new shares. The fundraising provides the biotech additional cash to pursue the development of ALX-0061, go after new deals and advance its preclinical work. Just days ago Ablynx said it had struck a collaboration with Spirogen on novel toxin-nanobody drug conjugates in cancer, the latest in a string of pacts. Release